SCHEMBL7837568

SCHEMBL7837568

CC(C)(C)C(=O)NN1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 3/20 0.42
HTT P42858 2/20 0.41
MAPT P10636 2/20 0.41
GAA P10253 2/20 0.38
CYP3A4 P08684 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
GLA P06280 1/20 0.38
ALOX12 P18054 1/20 0.38
NFKB1 P19838 1/20 0.38
BRPF1 P55201 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
LIPE Q05469 1/20 0.36
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
AKR1C3 P42330 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12265798 0.98 L3MBTL1 (0.49) L3MBTL1ALDH1A1HTTMAPTGAA
SCHEMBL10266497 0.78 CYP2D6 (0.46) HTTKDM4ELIPESMN1; SMN2
SCHEMBL27915480 0.78 GNAI3 (0.45) L3MBTL1ALDH1A1HTTMAPT
SCHEMBL28514252 0.77 L3MBTL1 (0.47) L3MBTL1ALDH1A1HTTMAPTGAA
SCHEMBL8861717 0.75 L3MBTL1 (0.43) L3MBTL1ALDH1A1HTTMAPTGAA
SCHEMBL3557996 0.74 L3MBTL1 (0.44) L3MBTL1ALDH1A1HTTMAPTGAA
SCHEMBL15054605 0.74 L3MBTL1 (0.45) L3MBTL1ALDH1A1HTTMAPTGAA
SCHEMBL6123494 0.73 HTT (0.45) L3MBTL1ALDH1A1HTTMAPTGAA
SCHEMBL637498 0.73 HTT (0.45) L3MBTL1ALDH1A1HTTMAPTGAA
Hydrochloric Acid SCHEMBL7939486 0.73 L3MBTL1 (0.43) L3MBTL1ALDH1A1HTTMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026368-B2 Hydrazide compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-09-27 US disclosed
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-10-08 US disclosed
EP-0977740-A4 METHODS FOR SYNTHESIZING 2-SUBSTITUTED IMIDAZOLES SEPRACOR INC (US) 2001-01-17 EP disclosed
EP-0977740-A1 METHODS FOR SYNTHESIZING 2-SUBSTITUTED IMIDAZOLES SEPRACOR, INC. (US) 2000-02-09 EP disclosed
WO-1998046571-A1 METHODS FOR SYNTHESIZING 2-SUBSTITUTED IMIDAZOLES SEPRACOR INC. (US) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, THPO, PTAFR L3MBTL1 2628/4885ALDH1A1 973/4885HTT 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.